Skip to main content
. Author manuscript; available in PMC: 2014 Jun 10.
Published in final edited form as: Exp Cell Res. 2013 Apr 12;319(10):10.1016/j.yexcr.2013.04.006. doi: 10.1016/j.yexcr.2013.04.006

Figure 3. Impact of PRC2 inactivation on epigenetic marks and PTEN expression in human CCSCs.

Figure 3

(A) Western blot analyses of H3K27me3, and H3K36me2 histone marks were performed on shLuc, shSUZ12, control/vehicle, and DZNep (5 μM, 48h) treated CCSCs. SUZ12 and PTEN protein levels were also evaluated for each condition. Actin was used as loading control. (B) Densitometry analysis of PTEN protein levels relative to actin levels for each condition tested in (A) is presented as a histogram (n=4; *: p=0.0417, **: p=0.007). (C) Promoter specific chromatin immunoprecipitations (ChIPs) were quantified using qPCR in control and DZNep treated (5 μM, 48h) hCCSC #1. Antibody directed against H3K27me3 or rabbit IgG was used for immunoprecipitation. Fragments of the human PTEN promoter and a random intergenic region were amplified from immunoprecipitated chromatin. Data are presented in histograms as fold over IgG (n=3; *: p<0.03). (D) Representative phase contrast microscopy pictures and TUNEL analyses of control (vehicle), DZNep (5 μM, 48h), VO-OHpic (300 nM, 48h), and DZNep + VO-OHpic treated hCCSC #1 line (n=3; *: p=0.0138, **: p≤0.0089).